Is REVB or RNA more undervalued in 2026?

CirclFi compares Revelation Biosciences, Inc. (REVB) and Atrium Therapeutics, Inc. (RNA) using 13 institutional-grade valuation models. REVB has a Quality of Company score of 4.1/10 while RNA scores 1.7/10.

Which is a better buy — REVB or RNA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do REVB and RNA valuations compare?

REVB at $1.10 and RNA at $13.36 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

REVB vs RNA Valuation Comparison 2026 — Intrinsic Value Analysis

REVB

Biotechnology

Revelation Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

LOW

Price

$1.10

Last close

Models

7/13

Active

RNA

Biotechnology

Atrium Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$13.36

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	REVB Fair Value	REVB Upside	RNA Fair Value	RNA Upside
Bayesian DCF	Intrinsic	$2.20	+99.8%	$3.54	-73.5%
Earnings Power Value	Intrinsic	—	—	$5.25	-61.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.68	+416.4%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for REVB vs RNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

REVB vs RNA — Which Stock Is More Undervalued?

REVB scores higher with a 4.1/10 quality rating vs RNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Revelation Biosciences, Inc. (REVB) and Atrium Therapeutics, Inc. (RNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

REVB currently trades at $1.10 with a QOC of 4.1/10, while RNA trades at $13.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).